<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma Ltd has filed a disclosure confirming that it does not qualify as a 'Large Corporate' under SEBI Circular SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, for Financial Year 2026-27. The company states it does not meet the applicability criteria thresholds that would classify it as a Large Corporate. This is a routine regulatory compliance filing submitted to both NSE and BSE. The disclosure was signed by CFO B. Adi Reddy and Company Secretary Santhanam Subramanian, dated April 24, 2026.
No direct impact on shareholders or stock price. This is a neutral compliance disclosure confirming regulatory standing. It simply indicates the company falls below the thresholds set by SEBI for Large Corporate norms, which carry additional disclosure and borrowing requirements.